New hardware boasts significant improvements
to reduce noise and generate higher fidelity signals
PLEASANTON, Calif., Nov. 7, 2024
/PRNewswire/ -- Movano Health Inc. (Nasdaq: MOVE) announced today
that it has tested its newly developed blood pressure wrist
wearable as part of its November
5th and 6th hypoxia clinical
trial that took place at the University of
California, San Francisco. The updated device features an
additional 12 mmWave antennas which together with Movano Health's
custom IC delivers enhanced data collection with less impact of
placement while also featuring a slimmer design, making it easier
and more comfortable to wear. In addition, the new wearable
monitors a host of other vital signs including pulse rate, blood
oxygen saturation (Sp02), respiration rate and ECG
waveforms.
"Our redesigned device is the culmination of months of testing
and refinement, and we are very excited to be able to put it to the
test in the clinical lab," said Movano Health's CTO and Founder
Michael Leabman. "The increased
number of RF antennas, as well as the addition of new signals for
enhanced sensor fusion, has resulted in a marked increase in
sensitivity and signal reliability from our previous design and
represents a significant leap forward in cuffless blood pressure
monitoring."
This study follows two clinical trials that took place in
October 2023 and June 2024 where the Company used its non-invasive
device to collect pulse pressure waveforms data from over 50
participants of varying gender, age, ethnicity and BMI. During each
session, participants wore Movano Health's wrist-worn device along
with a hospital-grade FDA-cleared vital signs monitor with cuffed
blood pressure measurements or utilized arterial blood pressure
data as the control. Learnings from these two studies prompted
device enhancements designed to deliver higher fidelity blood
pressure signals and ensure successful clinical results.
About Movano Health
Founded in 2018, Movano
Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring
(www.eviering.com), is developing a suite of purpose-driven
healthcare solutions to bring medical-grade data to the forefront
of wearables. Featuring modern and flexible form factors, Movano
Health's devices offer an innovative approach to delivering trusted
data to both customers and enterprises, capturing a comprehensive
picture of an individual's health data and uniquely translating it
into personalized and intelligent insights.
Movano Health is developing its proprietary technologies and
wearable medical device solutions to enable the future use of data
as a tool to proactively monitor and manage health outcomes across
a number of patient populations that exist in healthcare. For more
information on Movano Health, visit https://movanohealth.com/.
Forward Looking Statements
This press release contains
forward-looking statements concerning our expectations,
anticipations, intentions, beliefs, or strategies regarding the
future. These forward-looking statements are based on assumptions
that we have made as of the date hereof and are subject to known
and unknown risks and uncertainties that could cause actual
results, conditions, and events to differ materially from those
anticipated. Therefore, you should not place undue reliance on
forward-looking statements. Examples of forward-looking statements
include, among others, statements we make regarding plans with
respect to the commercial launches of the Evie Ring and EvieMED
Ring; our expectations regarding potential commercial
opportunities; planned cost-cutting initiatives; anticipated FDA
clearance decisions with respect to our products; expected future
operating results; product development and features, product
releases, clinical trials and regulatory initiatives; our
strategies, positioning and expectations for future events or
performance. Important factors that could cause actual results to
differ materially from those in the forward-looking statements are
set forth in our most recent Annual Report on Form 10-K and any
subsequent Quarterly Reports on Form 10-Q, and in our other reports
filed with the Securities and Exchange Commission, including under
the caption "Risk Factors." Any forward-looking statement in this
release speaks only as of the date of this release. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
UC Disclaimer
The information stated above was
prepared by Movano Health and reflects solely the opinion of the
corporation. Nothing in this statement shall be construed to imply
any support or endorsement of Movano Health, or any of its
products, by The Regents of the University of
California, its officers, agents and employees.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/movano-health-announces-completion-of-clinical-study-with-cuffless-rf-blood-pressure-device-302298233.html
SOURCE Movano
